Their late-stage drug pipeline includes novel treatments for genetic and neurodegenerative diseases, leveraging the expertise of their scientific founders from the University of Oxford and University of Munich. IntraBio's management team and business consultants have vast commercial and regulatory experience in drug product development, including all stages from small molecule manufacturing, clinical studies, and regulatory approvals in the USA and Europe. The company translates research in the fields of lysosomal biology, autophagy, and neurology into orphan drugs and treatments that will significantly improve the lives of patients, their caregivers, and families.